Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 14/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14545844 | 0.91 | GSK3B (0.53) | GSK3BMAPTTSHRCHEK1CDK2 | |
| SCHEMBL13120500 | 0.91 | GSK3B (0.71) | GSK3BMAPTTSHRCDK2 | |
| SCHEMBL12954467 | 0.91 | GSK3B (0.56) | GSK3BMAPTTSHRCHEK1PKM | |
| SCHEMBL13304919 | 0.88 | GSK3B (0.62) | GSK3BCHEK1CDK2 | |
| SCHEMBL14418828 | 0.87 | GSK3B (0.57) | GSK3BCHEK1CDK2KMT2A | |
| SCHEMBL14418829 | 0.85 | GSK3B (0.56) | GSK3BCHEK1CDK2 | |
| SCHEMBL14545273 | 0.82 | GSK3B (0.52) | GSK3BCHEK1CDK2KMT2A | |
| SCHEMBL13120569 | 0.82 | GSK3B (0.66) | GSK3BMAPTTSHRCDK2 | |
| SCHEMBL13120575 | 0.81 | GSK3B (0.70) | GSK3BCDK2 | |
| SCHEMBL13289009 | 0.81 | GSK3B (0.56) | GSK3BCHEK1PKMCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | SCHERING CORPORATION | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | CDK2, CDK5, CDKN1A | GSK3B 937/4885MAPT 2944/4885TSHR 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.